

Policy Tracker Archive

115th United States Congress (January 3rd, 2017 – January 3rd, 2019)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Allow government to regulate/require disclosure of patient assistance	[Improving Access to Affordable Prescription Drugs Act; Introduced 03/29/2017] Require independent charity assistance programs to disclose to the IRS the total amount of patient assistance provided to patients who are prescribed drugs manufactured by any contributor to the independent charity assistance program.	Sen. Franken (D-MN)
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[U.S. Budget FY 2019; Introduced 02/12/2018] Modify the 340B drug discount program to reward hospitals that provide significant charity care and reducing payment through the program to hospitals that provide little charity care.	U.S. Budget FY 2019
Accountability and Oversight	Establish drug pricing review board/committee	[Prescription Drug and Medical Device Price Review Board Act of 2018; Introduced 05/09/2018] Establish an Interagency Drug and Device Price Review Board to collect data on drug and device prices and manufacturing costs, and if necessary, take enforcement action against manufacturers that charge consumers excessive prices.	Rep. DeLauro (D-CT)
Accountability and Oversight	Establish drug pricing review board/committee	[Prescription Drug and Medical Device Price Review Board Act of 2018; Introduced 05/09/2018] Establish a Medical Device Price Review Board under the Department of Health and Human Services to regulate the prices of qualifying prescription drugs and medical devices. The Board will require manufacturers to report the price charged and the costs to produce and market the drug and the board can prescribe a formula to determine whether the average manufacturer price is an excessive price and the manufacturer will be prohibited against charging that excessive price.	Rep. DeLauro (D-CT)
Accountability and Oversight	Manufacturer Transparency	[Preserve Access to Affordable Generics Act; Introduced 01/12/2017] Require brand name manufacturers and generic manufacturers to submit to the Federal Trade Commission any other agreements the parties enter into within 30 days of entering into an agreement related to the manufacturing, marketing, sale, or exclusivity period of a drug.	Sen. Klobuchar (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Manufacturer Transparency	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Require the HHS Office of the Inspector General (HHS OIG) to monitor changes in drug prices and take steps to prevent drug manufacturers from engaging in price gouging. If price of a drug increases beyond medical inflation, the manufacturer would be subject to a graduated excise tax that depends on the size of the price increase, with prior assessment of the extent to which the price increase was due to changes in a drug's supply chain or for other justifiable reasons.	Sen. Franken (D-MN)
Accountability and Oversight	Manufacturer Transparency	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Require drug manufacturers to disclose costs of research, development, manufacturing, marketing, and acquisitions, as well as federal investments, revenues and sales, and other factors that influence drug prices, by product, to the Secretary of the Department of Health and Human Services (HHS), to be made publicly available in a searchable format.	Sen. Franken (D-MN)
Accountability and Oversight	Manufacturer Transparency	[Fair Accountability and Innovative Research Drug Pricing Act of 2017; Introduced 05/16/2017] Require manufacturers to notify HHS and submit a report 30 days before raising price of certain products by more than 10%. The report should contain justification and costs for manufacturing, R&D, along with net profits, and marketing and advertising.	Sen. Baldwin (D-WI)
Accountability and Oversight	Manufacturer Transparency	[Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017; Introduced 06/13/2017] Amend title XI of the Social Security Act to require drug manufacturers to submit justification of drug price increases within 60 days of determination of applicability of rule.	Sen. Wyden (D-OR)
Accountability and Oversight	Manufacturer Transparency	[U.S. Budget FY 2019; Introduced 02/12/2018] Require manufacturers to better report ASP for accurate payment rates.	U.S. Budget FY 2019
Accountability and Oversight	Manufacturer Transparency	[Affordable Medications Act; Introduced 09/05/2018] Propose to increase transparency by requiring drug	Sen. Smith (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		manufacturers to submit reports outlining the revenue and incurred cost of a drug.	
Accountability and Oversight	Manufacturer Transparency	[CURE High Drug Prices Act; 12/13/2018] Allows the Secretary of HHS to notify a manufacturer of its potential price gouging and require a justification of the increase.	Sen. Blumenthal (D-CT)
Accountability and Oversight	Provide evidence of clinical superiority to receive financial rewards	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Add a requirement that products awarded the 3-year New Clinical Investigation Exclusivity must show significant clinical benefit over existing therapies manufactured by the applicant in the 5-year period preceding the submission of the application.	Sen. Franken (D-MN)
Accountability and Oversight	Provider Transparency	[Ensuring the Value of the 340B Program Act of 2018; Introduced 02/27/2018] Require hospitals to provide information of drug acquisition costs for 340B drugs along with information on the hospital's revenues received for such drugs.	Sen. Grassley (R-IA)
Foster Competition	Drug importation for noncompetitive markets	[Short on Competition Act; Introduced 01/20/2017] Allow for the expedited approval and temporary importation of generic prescription drugs in the case of noncompetitive drug markets (fewer than five holders of approved applications for brand or generic versions of the drug, drug has been approved for at least 10 years, or patents on the active ingredient of a drug have expired).	Sen. Klobuchar (D-MN)
Foster Competition	Ensure competitive access to drug samples	[FAST Generics Act of 2017; Introduced 04/06/2017] Amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products.	Rep. McKinley (R-WV)
Foster Competition	Incentivize generic and biosimilar entry	[Lower Drug Costs through Competition Act; Introduced 01/30/2017] Revise provisions for the FDA to prioritize review of generic drug applications allowing for expedited inspection.	Rep. Schrader (D-OR)
Foster Competition	Incentivize generic and biosimilar entry	[Increasing Competition in Pharmaceuticals Act; Introduced 02/02/2017] Create a new "generic priority review voucher" that would be awarded to the sponsor of a successful application for a medical shortage or sole-source drug that makes it to market.	Sen. Collins (R-ME)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Incentivize generic and biosimilar entry	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Modify the New Chemical Entity (NCE) exclusivity period to allow generic drug application for the branded product after three years rather than five, but maintain market exclusivity for five years.	Sen. Franken (D-MN)
Foster Competition	Incentivize generic and biosimilar entry	[Making Pharmaceutical Markets More Competitive Act; Introduced 05/11/2017] Prioritize the review of, and act within 240 calendar days of the date of the submission of, an original abbreviated new drug application submitted for review under this subsection, or on a supplement to such an application, that is for a drug for which there are not more than 3 approved drugs listed.	Sen. Collins (R-ME)
Foster Competition	Incentivize generic and biosimilar entry	[U.S. Budget FY 2019; Introduced 02/12/2018] Give FDA greater ability to bring generic drugs to market quicker by granting power to approve a subsequently filed generic application for 180-day exclusivity when the first-to-file is not yet approved due to deficiencies.	U.S. Budget FY 2019
Foster Competition	Incentivize generic and biosimilar entry	[President's Blueprint; Introduced 05/01/2018] Allow the FDA to publish a list of drug names that have no competitors to encourage generic competitors to enter the market and bring prices down.	President's Blueprint
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Preserve Access to Affordable Generics Act; Introduced 01/12/2017] Prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.	Sen. Klobuchar (D-MN)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Preserve Access to Affordable Generics Act; Introduced 01/12/2017] Authorize the Federal Trade Commission to initiate proceedings against parties to any agreement that resolves or settles a patent infringement claim in connection with the sale of a drug.	Sen. Klobuchar (D-MN)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Make it illegal for brand-name and generic drug manufacturers to enter into agreements in which the brand-name drug manufacturer pays the generic manufacturer to keep more affordable generic equivalents off the market. Take away 180 day exclusivity	Sen. Franken (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		period for generic manufacturers entering into such an agreement.	
Foster Competition	Limit anticompetitive behaviors by manufacturers	[U.S. Budget FY 2019; Introduced 02/12/2018] Discourage generic manufacturers use of their 180-day exclusivity as the first generic to prevent other generic manufacturers from entering the market. Propose to start a drug company's 180-day exclusivity clock in cases when another generic application is waiting for approval, but is blocked by the first applicant's 180-day exclusivity.	U.S. Budget FY 2019
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Medications Act; Introduced 09/05/2018] Introduce measures to block unfair and anticompetitive drug monopoly practices to allow for generic competitors to come to market	Sen. Smith (D-MN)
Foster Competition	Reduce market monopoly	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Reduce the biological product exclusivity from 12 years to 7 years.	Sen. Franken (D-MN)
Foster Competition	Reduce market monopoly	[PRICED Act; Introduced 07/26/2018] Amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 7 years.	Rep. Schakowsky (D-IL)
Incentivize Innovation	Direct financial incentives	[Affordable Medications Act; Introduced 09/05/2018] Encourage innovation by setting aside a prize fund for the development new antibiotics and drugs	Sen. Smith (D-MN)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Know the Lowest Price Act of 2018; Introduced 03/14/2018] Amend the Social Security Act to ensure that health plans and pharmacy benefit managers cannot restrict pharmacies from providing individuals information on the differential price of the drug under the plan and without health-insurance coverage.	Sen. Stabenow (D-MI)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[COST Act; Introduced 07/31/2018] Amend the Public Health Service Act and Social Security Act to prevent health insurers, group health plans, Medicare Advantage organizations and prescription drug plan sponsors from restricting drug pricing information given to consumer.	Rep. Paulsen (R-MN)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; Introduced 03/15/2017] Amend titles XI and XVIII of the Social Security Act to provide	Sen. Wyden (D-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		public disclosure of information on rebates, discounts, and price concessions with respect to an individual drug or an individual plan on the HHS website. To allow patients and employers to compare PBMs negotiating capacity.	
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; Introduced 03/15/2017] Allow patients and employers to compare PBMs' ability to negotiate rebates, discounts, and price concessions passed through to plan sponsors by making this information publicly available on the internet.	Sen. Wyden (D-OR)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Require drug manufacturers to disclose costs of research, development, manufacturing, marketing, and acquisitions, as well as federal investments, revenues and sales, and other factors that influence drug prices, by product, to the Secretary of the Department of Health and Human Services (HHS), to be made publicly available in a searchable format.	Sen. Franken (D-MN)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Drug-Price Transparency in Communications Act; Introduced 11/16/2017] Require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.	Sen. Durbin (D-IL)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Transparent Health Care Pricing Act of 2018; Introduced 01/16/2018] Require entities that offer or furnish health care related products or services to the public to disclose the price for those products and services at the point of purchase or on the internet. The entities must disclose all prices, including wholesale, retail and discounted prices that are accepted as payment in full for products and services furnished to individual consumers.	Rep. Perlmutter (D-CO)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Drug-Price Transparency in Communications Act; Introduced 07/26/2018] Require drug manufacturers to include prescription drug prices on any DTC advertising and any marketing to practitioners of a drug.	Rep. Schakowsky (D-IL)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Limit Price Inflation	Implement inflation cap	[U.S. Budget FY 2019; Introduced 02/12/2018] Propose an inflation limit for reimbursement of Medicare Part B drugs.	U.S. Budget FY 2019
Limit Price Inflation	Implement inflation cap	[CURE High Drug Prices Act; Introduced 12/13/2018] Prohibit the gouging of drug prices by setting limit in drug price increase of a certain percent or more within a time period.	Sen. Blumenthal (D-CT)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Protecting Medicare from Excessive Price Increases Act of 2018; Introduced 03/01/2018] Amends the Social Security Act to require drug manufacturers to pay a Medicare part B rebate for qualifying drugs if the price of the drug increases faster than inflation.	Rep. Levin (D-MI)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[CURE High Drug Prices Act; Introduced 12/13/2018] In the event that drug prices increase beyond the listed percentage or more within a certain time period, the Secretary has the power to restore any excessive amount paid from the price increase to the consumer.	Sen. Blumenthal (D-CT)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Safe and Affordable Drugs from Canada Act of 2017; Introduced 01/09/2017] Amend the Federal Food, Drug, and Cosmetic Act to allow personal importation of safe and affordable drugs from approved pharmacies in Canada.	Sen. McCain (R-AZ)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Personal Drug Importation Fairness Act of 2017; Introduced 02/07/2017] Allow importation by persons other than a drug's manufacturer if the drug has the same active ingredients, route of administration, and strength as an approved drug, is imported or re-imported from a qualified country in which it is lawfully marketed, is dispensed by a licensed pharmacist, is shipped directly to, or is imported by, the ultimate consumer, in quantities that do not exceed a 90-day supply, is accompanied by a copy of a valid prescription, and is not a controlled substance.	Rep. Ellison (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable and Safe Prescription Drug Importation Act; Introduced 02/28/2017] Introduce regulation that allows wholesalers, pharmacies, and individuals to import prescription drugs from a list of certified foreign sellers, published on a dedicated website, and permit importation from OECD countries with standards for approval and sale of prescription drugs comparable to those in the United States.	Sen. Sanders (I-VT)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable and Safe Prescription Drug Importation Act; Introduced 02/28/2017] Allow individual importation of qualifying prescription drugs from Canada or another licensed foreign pharmacy.	Sen. Sanders (I-VT)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Allow wholesalers, licensed U.S. pharmacies, and individuals to import qualifying prescription drugs manufactured at FDA-inspected facilities from licensed Canadian sellers and, after two years, from OECD countries that meet standards comparable to U.S. standards. Imported drugs must have the same active ingredient, route of administration, and strength as drugs approved in the U.S., and the Secretary has suspension authority when sellers do not meet standards.	Sen. Franken (D-MN)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable Medications Act; Introduced 09/05/2018] Allow wholesale distributors, pharmacies, and individuals to import cheaper drugs from other countries.	Sen. Smith (D-MN)
Reduce costs and improve access for patients	Establish pricing requirements for drugs developed with federal support	[A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.; Introduced 07/31/2017] Require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.	Sen. Sanders (I-VT)
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; Introduced 03/15/2017] Require PDP sponsors to provide enrollees with the	Sen. Wyden (D-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
	enrolled in Medicare/Medicaid	negotiated price for covered drugs at point-of-sale.	
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients enrolled in Medicare/Medicaid	[U.S. Budget FY 2019; Introduced 02/12/2018] Require plans to share at the point-of-sale portions of the rebate received from manufacturers.	U.S. Budget FY 2019
Reduce costs and improve access for patients	Increase beneficiary choices under Medicare	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Amend the Social Security Act to ensure that each Part D eligible individual has a choice of at least three plans in the area in which the individual resides.	Sen. Cardin (D-MD)
Reduce costs and improve access for patients	Increasing manufacturer rebates to government programs	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Require manufacturers to provide rebates to CMS for drugs administered to low-income patients.	Sen. Cardin (D-MD)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Cancer Drug Parity Act of 2017; Introduced 03/07/2017] Amend the Public Health Service Act to require group and individual health insurance coverage and group health plans to provide for cost sharing for oral anticancer drugs on terms no less favorable than the cost sharing provided for anticancer medications administered by a health care provider.	Rep. Lance (R-NJ)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Close the Medicare Part D prescription coverage gap in 2018, two years earlier than under current law to expedite financial relief for seniors, and require drug manufacturers to pay a larger share of the costs during the coverage gap.	Sen. Franken (D-MN)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] For plan years beginning in 2019 and later, cap prescription drug cost sharing at \$250 per month for individuals and \$500 a month for families enrolled in Qualified Health Plans and employer-based plans.	Sen. Franken (D-MN)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[U.S. Budget FY 2019; Introduced 02/12/2018] Create a new Part D out-of-pocket spending cap.	U.S. Budget FY 2019

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[U.S. Budget FY 2019; Introduced 02/12/2018] Propose to exclude manufacturer discounts in calculation of beneficiary out-of-pocket costs in the coverage gap and establish an out-of-pocket cost maximum in the catastrophic phase. This policy is intended to have plans take more responsibility to negotiate with manufacturers to lower prices for high-cost drugs.	U.S. Budget FY 2019
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[U.S. Budget FY 2019; Introduced 02/12/2018] Propose to remove cost-sharing for generic drugs for low-income beneficiaries and require plans to apply a majority of the rebates at the point of sale.	U.S. Budget FY 2019
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Capping Prescription Costs Act of 2018; Introduced 07/11/2018] For plan years beginning in 2020, requires that all cost-sharing under a health plan pertaining to prescription drugs will not exceed \$250 per month for each enrolled individual or \$500 for each family. For plan years after 2020, the limitation will be increase by an amount equal to the product of that amount and the medical care component of the consumer price index for all urban consumers for that year.	Sen. Warren (D-MA)
Reduce costs and improve access for patients	Strengthen payer negotiating power by removing legal barriers	[U.S. Budget FY 2019; Introduced 02/12/2018] Propose a change in Part D formulary standards by requiring a minimum of one drug per class rather than two in order to strengthen Part D plans' negotiating power with drug manufacturers.	U.S. Budget FY 2019
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Prescription Drug Price Negotiation Act of 2017; Introduced 01/05/2017] Amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.	Sen. Klobuchar (D-MN)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Prescription Drug and Health Improvement Act of 2017; Introduced 02/09/2017] Amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries.	Sen. Franken (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Allow the Secretary of HHS to negotiate with drug companies to lower prescription drug prices, and direct the Secretary to prioritize negotiations on specialty and other high-priced drugs. If, after a year, the Secretary and drug manufacturers fail to successfully negotiate a fair price, the Secretary will use the price that the Department of Veterans Affairs or other federal agencies that purchase prescription drugs use.	Sen. Franken (D-MN)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017; Introduced 08/01/2017] Allow the Secretary of Health and Human Services to negotiate prescription drug prices under Part D of the Medicare program by striking the subsection of the Social Security Act that prohibits interference by the Secretary in negotiations between manufacturers, pharmacies, and plan sponsors, as well as requirements for a particular formulary or price structure for reimbursing Part D drugs.	Sen. Klobuchar (D-MN)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Drug Price Negotiation Act; Introduced 10/25/2017] Amend Social Security Act to provide for negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D and for other purposes.	Sen. Sanders (I-VT)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Negotiation and Competitive Licensing Act of 2018; Introduced 07/25/2018] Amend the Social Security Act and require the Secretary of HHS to negotiate prices of prescription drugs under Medicare Part D. The Secretary will use clinical and cost effectiveness, budgetary impact, number of similarly effective drugs, associated patient financial burden, unmet patient need for the drug and total global revenue obtained by the manufacturer in order to negotiate such prices.	Rep. Doggett (D-TX)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Fair Drug Pricing Act of 2018; Introduced 07/26/2018] Require the Secretary of HHS to negotiate prices of certain drugs with the manufacturer. In the	Rep. Schakowsky (D-IL)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		case that there is a failure to negotiate the price, the Secretary will set the price based on criteria set forth by the bill.	
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Prescription Drug Savings and Choice Act of 2018; Introduced 07/26/2018] Allow the Secretary to enter into negotiations with pharmaceutical manufacturers to minimize the cost of Part D drugs for eligible individuals who are enroll in the plan.	Rep. Schakowsky (D-IL)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Affordable Medications Act; Introduced 09/05/2018] Improve access and affordability by allowing Medicare to negotiate prescription drugs prices, charging drug companies that raise drug prices substantially.	Sen. Smith (D-MN)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Allow Medicare to negotiate drug prices with manufacturers.	Sen. Cardin (D-MD)
Reduce costs for government health programs	Alter payment rates	[To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes; Introduced 04/05/2017] Amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the ASP for drugs and biologicals under Medicare, and for other purposes.	Rep. Upton (R-MI)
Reduce costs for government health programs	Expand 340B program to cover more drugs	[Closing Loopholes for Orphan Drugs Act; Introduced 06/13/2017] Amend the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (drugs for rare conditions), to expand the discount to orphan drugs not being used to treat rare diseases.	Rep. Welch (D-VT)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; Introduced 03/15/2017] Establish a minimum percent of aggregate amount of rebates, discounts or price concessions that a PBM negotiates that is attributable to patient utilization under the plan to be passed through to the plan sponsor.	Sen. Wyden (D-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Medicare Drug Savings Act of 2017; Introduced 02/01/2017] Amend title XVIII of the Social Security Act to require drug manufacturers to provide rebates for drugs dispensed to low-income individuals under the Medicare prescription drug benefit program.	Sen. Nelson (D-FL)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Improving Access To Affordable Prescription Drugs Act; Introduced 03/29/2017] Restore prescription drug rebates from manufacturers to Medicare for seniors dually eligible for Medicare and Medicaid and extends these rebates to other Medicare patients in Medicare low-income subsidy (LIS) plans.	Sen. Franken (D-MN)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.; Introduced 01/03/2019] Sunset the limit on the maximum rebate amount under Medicaid.	Rep. Burgess (R-TX)
Reduce costs for government health programs	Limiting add-on payments to providers	[U.S. Budget FY 2019; Introduced 02/12/2018] Reduce WAC-based payment amounts (to providers for new drugs during the initial period) if ASP is unavailable.	U.S. Budget FY 2019
Reduce costs for government health programs	Utilize international reference pricing	[Low Drug Prices Act; Introduced 11/29/2018] Require the Secretary of HHS to create annual reference prices for prescription drugs for Federal health programs. The annual reference prices will be determined by the median price for the same drug in reference countries.	Sen. Merkley (D-OR)